Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06203210 · ClinicalTrials.gov registry record · Phase 3
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
A Phase 3 study of Small-cell Lung Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT06203210: Recruiting Phase 3 study of Small-cell Lung Cancer, sponsored by Daiichi Sankyo.
NCT06203210 is a Phase 3 study of Small-cell Lung Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 540 participants, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (140% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06203210, a Phase 3 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Primary Outcome
OS is defined as the time interval from the date of randomization to the date of death due to any cause.
Conditions Studied
Interventions
- DRUG Topotecan
- DRUG Lurbinectedin
- DRUG Ifinatamab deruxtecan
- DRUG Amrubicin
Study Locations (20)
California
- Clinical Research Providence Medical Foundation - Fullerton
- UCLA Hematology-Oncology - Los Angeles
- UCSF Mission Bay Mission Hall - San Francisco
Florida
- University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center - Miami
- AdventHealth Orlando, Cancer Institute - Orlando
- H. Lee Moffitt Cancer Center and Research Institute, Inc - Tampa
Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
- John Hopkins School of Medicine - Baltimore
New Jersey
- Astera Cancer Care - East Brunswick
- Meridian Health Systems - Neptune City
New York
- Clinical Research Alliance, Inc - Lake Success
- New York University Cancer Center - Laura and Isaac - New York
Arkansas
- Highlands Oncology Group - Springdale
Illinois
- Rush MD Anderson Cancer Center - Chicago
Kentucky
- Baptist Health Lexington - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2029-02-22 |
| Phase | Phase 3 |
What NCT06203210 shows while recruiting
NCT06203210 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (140% higher).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Topotecan is the first listed.
NCT06203210 names 20 study sites across 13 states, led by California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06203210 about?
NCT06203210 is a clinical study titled "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer". This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
What is the current status of trial NCT06203210?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2024-05-21. Estimated completion is 2029-02-22.
What conditions does trial NCT06203210 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT06203210?
The interventions under investigation include: Topotecan (DRUG), Lurbinectedin (DRUG), Ifinatamab deruxtecan (DRUG), Amrubicin (DRUG).
Who is sponsoring clinical trial NCT06203210?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06203210 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06203210's enrollment target sits among peer trials
540 10th of 79 higher than 70 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI